Announcement

Collapse
No announcement yet.

HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox Preparedness

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox Preparedness

    FOR IMMEDIATE RELEASE
    July 1, 2022


    Order will bring federal government’s rapidly available supply to more than 4 million vaccines

    The U.S. Department of Health and Human Services (HHS) today ordered an additional 2.5 million doses of Bavarian Nordic's JYNNEOS, an FDA-licensed vaccine indicated for prevention of smallpox and monkeypox, for use in responding to current or future monkeypox outbreaks and as part of U.S. smallpox preparedness. Deliveries from this latest order will begin arriving at the Strategic National Stockpile (SNS) later this year and will continue through early 2023.

    The additional supply of vaccines is part of the Biden-Harris Administration's broader strategy to combat the monkeypox virus and protect those most at risk, including by accelerating the production and distribution of vaccines, making testing more accessible and convenient, and communicating regularly with health and community leaders about the virus.

    "We are working around-the-clock with public health officials in states and large metro areas to provide them with vaccines and treatments to respond to the current monkeypox outbreak," said HHS Secretary Xavier Becerra. "This order of additional JYNNEOS vaccine will help us push out more vaccine quickly, knowing that we have more doses on the way in the coming months – and is only possible because of our longstanding investment in smallpox and monkeypox preparedness."

    The order announced today is in addition to the 500,000 doses of government-owned vaccine the company is producing in 2022 for use in the current response to monkeypox in the U.S and brings the total vaccine doses to be delivered in 2022 and 2023 to more than 4 million. The company will produce these doses in liquid frozen form using vaccine already manufactured in bulk under an existing 10-year contract with the Biomedical Advanced Research and Development Authority (BARDA), within the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR); that contract was part of ongoing national preparedness efforts against smallpox. ...

Working...
X